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Community-acquired pneumonia (CAP) is a common and
serious illness. Analyses of administrative data show that large
variations exist in admission rates, length of hospital stay, and
use of institutional resources. OBJECTIVES: This study evalu-
ated the medical management of patients hospitalized with Com-
munity Acquired Pneumonia (CAP) in an urban inner-city public
hospital. The study was undertaken to identify areas for quality
improvement. METHODS: A retrospective chart review was
used to collect data on patients admitted to the hospital with a
diagnosis of CAP during the period January 1, 2003 to April 30,
2004. Data were collected based on American Thoracic Society
(ATS) criteria. RESULTS: Medical records of 155 patients were
reviewed; overall mortality rate was 4%; 80% of patients
received their ﬁrst antibiotic dose in less than eight hours; 97%
of patients had their oxygenation checked within 24 hours of
admission. Only 45% of patients had at least one culture per-
formed prior to initiation of antibiotics. The most commonly
prescribed antibiotic was levoﬂoxacin, representing 39% of all
antibiotic orders. Using the ATS guidelines, 14 (9%) patients
were considered to have received inappropriate antimicrobial
treatment. Of these patients, 7 had severe cases of CAP requir-
ing admission to an intensive care unit (ICU). The average length
of stay for all patients was 7.64 days (SD + 0.327). Patients who
received an antibiotic regimen that covered both typical and
atypical organisms, as compared to those who did not, had a
shorter length of therapy (7.33 days vs. 9.79 days, p < 0.05).
CONCLUSION: Ongoing analysis of inpatients with CAP will
provide information to evaluate improvement of clinical out-
comes and to identify areas of focus for future performance
improvement activities.
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OBJECTIVES: To evaluate the effect of drotegogin alfa (DA) on
bleeding events in patients with severe sepsis and multiple organ
failures. METHODS: A pre-post design was conducted before
and after DA’s market introduction. An optimal propensity score
matching method was undertaken to control for unbalanced
characteristics. Several models were tested to explain the number
of bleedings events. The more usual ones are the Poisson and the
negative binomial (NB) models. Contrary to the NB model,
including a dispersion parameter, the Poisson model supposes the
mean equals the variance. An alternative consists on modeling
separately the probability of experiencing at least one bleeding
(with a binomial model) and the number of bleeding events (with
a count model). Double-hurdle models suppose that, once a
threshold has been exceeded, patients experience at least one
bleeding event. In zero inﬂated models, both models can predict
an event absence. Non-nested models were compared with the
Vuong statistic. RESULTS: The matched sample includes 840
patients. Bleeding events were experienced by 17.6% of patients,
13.6% in the before and 21.7% in the after phase (p = 0.0021).
The mean number of bleedings was higher in DA treated patients
(0.28 against 0.18, p = 0.0208). The standard NB model ﬁtted
better than the double-hurdle NB model (p < 0.0001) and was
similar to the zero-inﬂated NB model (p = 0.6815). We kept the
NB model, the simpler one. Moreover, the dispersion parameter
was signiﬁcant (p = 0.0013), favouring the NB to the Poisson
model. In this multivariate model, patients in the after phase
were still more at risk of experiencing bleeding events. Other risk
factors included the presence of a central catheter infection and
a high LODS score. CONCLUSIONS: DA use in addition to the
conventional treatment leads to more bleeding events. In our
study, over-parameterised models did not bring more informa-
tion than simpler ones.
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OBJECTIVES: To evaluate the share of antibiotic therapy cost
in total treatment costs for nosocomial and community acquired
infections. METHODS: Systematic literature search
(1996–2003) using the major online databases and additional
manual search yielded 1211 references (selection Ia). Studies
were divided up to 11 different diagnostic groups that were con-
sidered to be most relevant (selection Ib). Inclusion and exclu-
sion criteria were applied for the selection Ic. Study quality was
assessed with a consolidated quality score comprising 23 ques-
tions. A study was assessed as “qualiﬁed” for further analyses,
if at least 50% of maximum points were achieved in a review
conducted by two independent reviewers. This resulted in the
selection of 44 studies (selection II) that were subject to a detailed
metaanalysis. RESULTS: The percentage of antibiotic costs in
relation to total direct costs was low: nosocomial pneumonia (N
= 3, 1.4–13.7%, SD: 5.5), respiratory tract infections (N = 2,
10–24.8%, SD: 5.3), community acquired pneumonia (N = 14,
0.64–57.84%, SD: 24.65), chronic bronchitis (N = 6,
1.1–66.66%, SD: 17.19), urinary tract infection (N =
3.5–33.82%, SD: 14.85), intraabdominal infection (N = 2,
3.2–19.38%, SD: 5.26), surgical prophylaxis (N = 2, 0.1–83.8%,
SD: 33.02), otolaryngological infections (N = 4, 14.18–60.1%),
STD (N = 1, 0.15–3.3%, SD: 2.23), Helicobacter pylori infec-
tions (N = 3, 2.34–45.49%, SD: 16.36), Clostridium difﬁcile
infections (N = 3, 0.07–1.20%, SD: 0.51). CONCLUSIONS:
This review showed that costs of antibiotic treatment were low
compared to overall direct treatment costs for most frequent
infections regardless of the differences in design and quality of
studies. The experience from this review may also contribute to
further development of evidence-based guidelines for conducting
pharmacoeconomical studies.
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OBJECTIVE: An estimated 1.25 million Americans are chroni-
cally infected with hepatitis B virus, many of whom develop
severe and potentially fatal liver diseases. Despite the high preva-
lence and serious health consequences, little is about the impact
on quality of life of disease states resulting from chronic HBV
infection. The objective was to estimate preferences (ratings and
utility weights) for six hepatitis B-related disease states among
infected persons. METHODS: Utility weights for six disease-
related health states were elicited from a sample of 56 patients
chronically infected with HBV in San Francisco using a standard
gamble. Probability wheels with 2-color pie charts for the rela-
tive probabilities of perfect health and death were employed as
props. RESULTS: The mean age was 51y (standard deviation:
12, range: 20 to 77y) and 77% were men. Mean utilities were:
0.72 (95% conﬁdence interval: 0.68; 0.79) for chronic hepatitis
B; 0.70 (0.65; 0.77) for compensated cirrhosis; 0.42 (0.35; 0.47)
for decompensated cirrhosis; 0.48 (CI: 0.40; 0.52) for hepato-
cellular carcinoma; 0.62 (0.56; 0.67) in the ﬁrst year after liver
transplant; and 0.72 (0.65; 0.77) after ﬁrst year post-transplant.
CONCLUSION: These utility values, the ﬁrst published on
patients in the United States, indicate that health states resulting
from chronic HBV infection substantially lower patients’ quality-
of-life. These preferences (utility weights) for health states can
be incorporated into many aspects of medical decision making,
including summary measures of health related quality of life,
monitoring population health, bedside clinical decision making,
and in technology assessment. For all health states, the utilities
collected here were lower than published estimates that are based
on clinicians opinion.
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OBJECTIVE: Although the incidence of the hepatitis B virus in
the UK is low, persons with chronic infection can develop severe
and potentially fatal liver diseases. The objective was to estimate
preferences (ratings and utility weights) for six hepatitis B-related
disease states among uninfected and infected persons.
METHODS: Three hepatologists characterized the typical effects
of symptoms on health-related quality of life. Standard gamble
(SG) utility weights for six disease-related health states were
elicited from a sample of 100 uninfected persons and 87 patients
chronically infected with HBV in the UK. Probability wheels
with 2-color pie charts for the relative probabilities of perfect
health and death were used as props. RESULTS: The mean age
of patients was 43y and 46y for uninfected persons; and 57%
and 47% were men, respectively. For patients and uninfected
persons, respectively, mean SG utilities were: 0.77 (95% conﬁ-
dence interval: 0.71; 0.81) and 0.82 (0.78, 0.85); for chronic
hepatitis B; 0.73 (0.65, 0.77) and 0.83 (0.80, 0.87) for compen-
sated cirrhosis; 0.34 (0.25, 0.39) and 0.36 (0.30, 0.42) for
decompensated cirrhosis; 0.36 (0.28, 0.41) and 0.46 (0.39, 0.52)
for hepatocellular carcinoma; 0.56 (0.49, 0.62) and 0.71 (0.65,
0.76) in the ﬁrst year after liver transplant; and 0.67 (0.59, 0.73)
and 0.82 (0.78, 0.86) after ﬁrst year post-transplant. CON-
CLUSION: These utility values, the ﬁrst published on patients
or uninfected persons in the UK, indicate that health states result-
ing from chronic HBV infection substantially lower patients’
quality-of-life. The mean SG utilities were systematically lower
for infected than for uninfected persons. These preferences for
health states can be incorporated into many aspects of medical
decision making, including summary measures of health related
quality of life, monitoring population health, bedside clinical
decision making, and in technology assessment.
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OBJECTIVES: To compare the direct health costs of HIV-
positive patients reporting sub-optimal intake of antiretroviral
therapy (ART) with those of patients reporting full adherence.
METHODS: 546 subjects from the Italian multicenter observa-
tional study ICoNA (Italian Cohort Naive Antiretrovirals) were
followed between 1997 and 2004. Non-adherence to ART was
assessed by a self-administered questionnaire. Medical costs
incurred by the National Health Service were calculated retro-
spectively as from ﬁrst ART and expressed in constant 1997
prices. RESULTS: Mean time on ART was 5.75 years (range
1.04–7.77); mean HIV-RNA and CD4 cells at baseline were 4.75
log10 copies/ml (range 1.3–6.6) and 307/ml (range 0–1309). Non-
adherence was reported by 197 (36%) patients, who showed a
higher number of new AIDS-deﬁning events (p = 0.01), of
detectable viremia episodes (p < 0.001), and of ART changes 
(p = 0.01). Overall medical costs and ART costs per year were
on average €6392 (range €555–€42,183) and €5373 (range
€537–€35,582), respectively, and did not signiﬁcantly differ
between the two groups. Annual inpatient costs were higher in
the non-adherent group (€432; 95%CI €256–€608) than in the
adherent group (€198; 95%CI €127–€269; p < 0.005). On mul-
tivariate linear regression, higher HIV-RNA, lower nadir and
baseline CD4, fewer ART changes, and interaction between low
adherence and number of therapy switches were independently
associated with higher log-transformed ART costs per year.
Older age, HCV co-infection, sub-optimal ART adherence, lower
CD4 nadir, and higher baseline CD4 were independently associ-
ated with higher annual inpatient costs, based on multivariate
tobit analysis. CONCLUSIONS: Non-adherence is common
among HIV-positive patients and is associated with virological
failure, disease progression, more frequent hospitalizations 
and treatment changes. Total and ART costs do not seem to be
signiﬁcantly affected by non-adherence, probably because of
switches to simpler and less expensive treatment options,
whereas inpatient costs are signiﬁcantly increased by sub-optimal
drug intake.
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OBJECTIVE: To analyse the efﬁciency of adding Enfuvirtide
(ENF) to an Optimised Therapy (OT) in HIV patients who are
